1. Home
  2. PRPO vs MBIO Comparison

PRPO vs MBIO Comparison

Compare PRPO & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$23.50

Market Cap

32.4M

Sector

Industrials

ML Signal

N/A

MBIO

Mustang Bio Inc.

HOLD

Current Price

$1.09

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPO
MBIO
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.4M
4.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRPO
MBIO
Price
$23.50
$1.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.1K
98.0K
Earning Date
11-14-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,800,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.95
N/A
52 Week Low
$3.90
$0.89
52 Week High
$28.50
$21.95

Technical Indicators

Market Signals
Indicator
PRPO
MBIO
Relative Strength Index (RSI) 50.72 39.03
Support Level $24.00 $1.05
Resistance Level $25.03 $1.31
Average True Range (ATR) 1.32 0.08
MACD -0.29 -0.01
Stochastic Oscillator 35.65 13.88

Price Performance

Historical Comparison
PRPO
MBIO

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: